We will leverage large-scale multi-omics datasets with state-of-the-art technologies to inform
novel targets for CAR T-cell therapy, ultimately aiding in improving survival outcomes.
What are the goals of this project?
We will re-analyze the HGG RNAseq fastq files using TGen's RNAseq analysis pipeline and
determine alternative splicing events using the tool Spladder. We will use the splice variant
analysis pipeline developed by TGen to determine differential splicing events between tumors
and controls as well as their protein level effects. With the help of TGen's neoantigen prediction
pipeline, we will also predict putative strong binding neopeptide candidates to MHCI and
MHCII. Following this, we will align our results with those generated by Dr Adam Resnick's
group for prioritization of splice events specific to tumors that could potentially lead to expression of neoepitopes in HGG.
Patrick Pirrotte, PhD
Patrick Pirrotte graduated with a Ph.D. in Neurobiology from Louis Pasteur University, Strasbourg, France (now University of Strasbourg) in November 2007. His semi-industrial thesis pioneered the use of high-resolution dynamic Secondary Ion Mass Spectrometry in Life Sciences. Since late 2013, Patr
Apurva Hegde, MS
Rebecca Halperin, PhD
Dr. Halperin is broadly interested in developing and applying methods to gain insight from cancer genomic data that can improve our understanding or tumor biology and inform clinical decision-making. Her current research focuses on the following areas 1) improving calling of variants in difficult s
Nicholas Schork, PhD
Nicholas J. Schork is Deputy Director and Distinguished Professor of Quantitative Medicine at The Translational Genomics Research Institute (TGen) in Phoenix, AZ. Dr. Schork is also Adjunct Professor of Population Sciences as well as Molecular and Cellular Biology at City of Hope, Adjunct Professor
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test